




RealRate

PHARMACEUTICAL 2017

Skye Bioscience Inc.
Rank 295 of 313



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2017

Skye Bioscience Inc.
Rank 295 of 313

The relative strengths and weaknesses of Skye Bioscience Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Skye Bioscience Inc. compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 911% points. The greatest weakness of Skye Bioscience Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 1,104% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,364%, being 947% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	279
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	662
Liabilities, Non-Current	1,112
Other Assets	34
Other Compr. Net Income	0
Other Expenses	-1,341
Other Liabilities	0
Other Net Income	0
Property and Equipment	9.6
Research and Development	939
Revenues	0
Selling, General and Administrative Expense	3,532

Output Variable	Value in 1000 USD
Assets	323
Liabilities	1,774
Expenses	3,130
Stockholders Equity	-1,451
Net Income	-3,130
Comprehensive Net Income	-3,130
Economic Capital Ratio	-1,364%

